The 10-second takeaway
For the quarter ended March 31 (Q1), Chemtura missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue contracted. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped to a loss.
Margins contracted across the board.
Chemtura logged revenue of $606.0 million. The seven analysts polled by S&P Capital IQ expected sales of $638.9 million on the same basis. GAAP reported sales were 14% lower than the prior-year quarter's $708.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.15. The seven earnings estimates compiled by S&P Capital IQ averaged $0.19 per share. Non-GAAP EPS of $0.15 for Q1 were 21% lower than the prior-year quarter's $0.19 per share. GAAP EPS were -$0.23 for Q1 versus $0.22 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 20.8%, 340 basis points worse than the prior-year quarter. Operating margin was 2.6%, 350 basis points worse than the prior-year quarter. Net margin was -3.8%, 690 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $794.4 million. On the bottom line, the average EPS estimate is $0.56.
Next year's average estimate for revenue is $2.84 billion. The average EPS estimate is $1.52.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 25 members out of 28 rating the stock outperform, and three members rating it underperform. Among six CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give Chemtura a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemtura is outperform, with an average price target of $29.00.
Looking for alternatives to Chemtura? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Chemtura to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.